Tuesday, 15 September 2015

Full text of “Leiomyosarcoma forecast 2020"

This report provides comprehensive information on the therapeutic development for Leiomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leiomyosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.


- The report provides a snapshot of the global therapeutic landscape of Leiomyosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Leiomyosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Leiomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Leiomyosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Table Of Content

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Leiomyosarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Leiomyosarcoma - Overview 8
Pipeline Products for Leiomyosarcoma - Comparative Analysis 9
Leiomyosarcoma - Therapeutics under Development by Companies 10
Leiomyosarcoma - Therapeutics under Investigation by Universities/Institutes 11
Leiomyosarcoma - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Leiomyosarcoma - Products under Development by Companies 15
Leiomyosarcoma - Products under Investigation by Universities/Institutes 16
Leiomyosarcoma - Companies Involved in Therapeutics Development 17
Karyopharm Therapeutics, Inc. 17
Merck & Co., Inc. 18
Mirati Therapeutics Inc. 19
Novartis AG 20
Pharma Mar, S.A. 21
Vicore Pharma AB 22
Leiomyosarcoma - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
C-21 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Cell Therapy to Target LMP-1 and LMP-2 for Oncology - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
everolimus - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
mocetinostat - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NOV-110501 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
pazopanib hydrochloride - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46

Request A Sample copy of This Report @ http://www.hexareports.com/sample/46616

pembrolizumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
selinexor - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
trabectedin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Leiomyosarcoma - Recent Pipeline Updates 69
Leiomyosarcoma - Dormant Projects 101
Leiomyosarcoma - Discontinued Products 102

About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Information:

Ryan Shaw

Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
Our Website: http://www.hexareports.com/ 

No comments:

Post a Comment